Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link
Dow Jones Industrial Average
) is trading up 10 points at 16,082 as of Tuesday, Nov 26, 2013, 11:55 a.m. ET. During this time, 110.5 million shares of the 30 Dow components have changed hands vs. an average daily trading volume of 378.7 million. The NYSE advances/declines ratio sits at 1,554 issues advancing vs. 1,348 declining with 127 unchanged.
- EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.
Holding back the Dow today is
), which is lagging the broader Dow index with a six-cent decline (-0.1%) bringing the stock to $49.60. Volume for Merck currently sits at 6.3 million shares traded vs. an average daily trading volume of 14 million shares.
Merck has a market cap of $143 billion and is part of the health care sector and drugs industry. Shares are up 21.3% year to date as of Monday's close. The stock's dividend yield sits at 3.5%.
Merck & Co., Inc. provides various health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products worldwide. The company has a P/E ratio of 32.9, above the S&P 500 P/E ratio of 17.7.
TheStreet Ratings rates Merck as a
. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, good cash flow from operations, expanding profit margins and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had sub par growth in net income.
- You can view the full Merck Ratings Report.